Journal
NEUROSCIENCE LETTERS
Volume 454, Issue 3, Pages 229-232Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2009.03.049
Keywords
VMAT2; Dopamine; Fluoxetine; Synaptic vesicle
Categories
Funding
- Foundation for Promotion of Material Science and Technology of Japan, MEXT [17025054]
- MHLW [H19-Iyaku-023, H17-Pharmaco-001, H16-Iyaku-029,18A-3]
- Naito Foundation
- Grants-in-Aid for Scientific Research [17025054] Funding Source: KAKEN
Ask authors/readers for more resources
The neuronal vesicular monoamine transporter (VMAT2) is the target molecule of action of some psychostimulants, such as methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA). The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on VMAT2 activity by measuring adenosine triphosphate-dependent [H-3]dopamine uptake into synaptic vesicles prepared from rat striatum. SSRIs, fluoxetine, paroxetine, and fluvoxamine, inhibited vesicular [3H]dopamine uptake in vitro. The rank order of potency was reserpine >> fluoxetine. paroxetine > fluvoxamine. methamphetamine > MDMA. Moreover, kinetic analysis revealed that inhibition by reserpine. a typical VMAT2 inhibitor. was uncompetitive, decreasing maximum velocity and affinity for dopamine. Inhibition by fluoxetine was noncompetitive, only decreasing maximum velocity for dopamine. These results suggest that fluoxetine inhibited the activity of VMAT2 by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available